Compare Ford Motor Company (F) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Recursion Pharmaceuticals Inc — how do they compare? Ford Motor Company trades at $12.19 (market cap $48.85B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Ford Motor Company is far larger — about 22.8× Recursion Pharmaceuticals Inc's market cap, and Ford Motor Company pays a 4.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| F | RXRX | |
|---|---|---|
Market Cap | $48.85B | $2.14B |
Volume | 57,748,965 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $6.79 |
52-Week Low | $11.21 | $2.84 |
Typical Hold Time | 104 Days | 22 Days |
Enterprise Value | $180.81B | $1.66B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.23, up 0.87% with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and high debt levels. Recent news highlights a 6.6% Q3 sales decline and supplier disruptions affecting F-150 production, though the company maintains its No. 3 U.S. sales position.
The outlook remains challenging with persistent losses and competitive pressures, though analyst consensus suggests 30% upside to the $15.90 price target. Key risks include ongoing operational issues, high leverage, and market share erosion to Asian rivals. Investment appeal hinges on execution improvements and hybrid vehicle transition success.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
